New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2013
07:08 EDTSPPISpectrum reports Q4 EPS 27c, consensus 26c
Reports Q4 revenue $70.1M, consensus $69.87M.
News For SPPI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
07:04 EDTSPPISpectrum presents new data on Evomela
Spectrum Pharmaceuticals announced results of a clinical study of the stability of Captisol-enabled Melphalan versus the currently marketed, propylene glycol-containing melphalan formulation entitled, Solution Stability of Captisol-enabled Melphalan vs Marketed Melphalan Products. These results were presented in an oral presentation at the annual American Pharmacists Association Annual Meeting & Exposition in San Diego, California.“The improved stability of EVOMELA may potentially ensure that cancer patients receive the full, intended therapeutic dose of intravenous melphalan, by increasing the use time and infusion time, and simplifying clinical administration logistics,” said Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer of Spectrum Pharmaceuticals. “EVOMELA is a new injectable formulation of melphalan that incorporates the Captisol brand of modified β-cyclodextrin improving the solubility and stability of melphalan. It also uses a standard aqueous diluent for reconstitution, instead of propylene glycol, which is associated with toxicities including renal dysfunction and arrhythmias. We look forward to launching EVOMELA with our existing sales force later this year and providing this new treatment option to cancer patients.”

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use